Nursing care
Alteplase: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Alteplase is a tissue plasminogen activator that dissolves clots by converting plasminogen to plasmin. Once it is running, no injections and no invasive lines are permitted, and neurological checks are done every 15 minutes for the first hour. Any new headache, confusion or focal deficit is treated as a bleed until imaging proves otherwise.
Mechanism, simply
Alteplase is a recombinant tissue plasminogen activator. It binds to fibrin within a clot and converts trapped plasminogen into plasmin, the enzyme that breaks down the fibrin mesh holding the clot together. The clot dissolves, blood flow returns, and in ischaemic stroke or acute MI that restored flow is what limits tissue death.
The drug does not distinguish neatly between a pathological clot and a clot that is doing its job, such as one sealing a recent puncture site or a surgical wound. That is the reason the nursing precautions around this drug are so absolute: any breach in the vasculature becomes a bleeding risk for as long as the drug's fibrinolytic effect lasts, roughly the infusion period plus several hours afterward.
Indications you will see on the ward
The two indications you will encounter most often are acute ischaemic stroke within the eligible treatment window, typically up to 4.5 hours from symptom onset depending on institutional protocol, and ST-elevation myocardial infarction when primary PCI is not rapidly available. It is also used for massive pulmonary embolism with haemodynamic instability and for clearing occluded central venous catheters at a much lower, localised dose.
Eligibility for systemic thrombolysis depends on a strict checklist run before the drug is ever drawn up: time of symptom onset, current anticoagulant use, recent surgery or trauma, blood pressure control, and imaging that rules out haemorrhage. The window is narrow and unforgiving, which is why stroke teams work against the clock from the moment a patient arrives.
Assessment before administration
Baseline neurological assessment using a standardised tool such as the NIH Stroke Scale is essential before the infusion starts, both to confirm the deficit and to give a reference point for detecting deterioration afterward. Blood pressure must be within the protocol-defined limit, commonly below 185/110 mmHg for stroke, before the drug can be given at all.
Review the patient's medication history and recent procedures for anything that raises bleeding risk: anticoagulants, recent surgery, arterial puncture at a non-compressible site, or a history of intracranial haemorrhage. Confirm IV access is established before the infusion, because once alteplase is running, no new injections and no invasive lines are permitted. If access is needed, it has to go in beforehand.
Toxicity and the antidote
There is no specific reversal agent for alteplase. If serious bleeding occurs, treatment is supportive: stop the infusion immediately, and the team may give cryoprecipitate to replace fibrinogen, tranexamic acid or aminocaproic acid as antifibrinolytics, and fresh frozen plasma or platelets depending on the clinical picture and local protocol.
The most feared complication is intracranial haemorrhage, which is why neurological checks are done every 15 minutes for the first hour after the infusion starts, then at wider intervals as the risk period passes. Any new headache, sudden change in level of consciousness, new weakness, or worsening of the original deficit is treated as a bleed until a CT scan proves otherwise, not investigated as a coincidental finding.
Interactions that matter
Concurrent use of anticoagulants such as heparin or warfarin, or antiplatelet agents such as aspirin and clopidogrel, compounds bleeding risk substantially, which is why recent use of these drugs is part of the eligibility screen rather than an afterthought. NSAIDs carry the same concern through their effect on platelet function.
Other thrombolytics should never be combined with alteplase, and herbal supplements with antiplatelet properties, such as ginkgo biloba or high-dose fish oil, are worth asking about specifically since patients rarely volunteer them. Once the infusion is complete, anticoagulants and antiplatelets are typically held for a defined period, often 24 hours, before being restarted, and that decision sits with the prescribing team based on repeat imaging.
What the patient must be told
Before the infusion, explain that this drug works by dissolving the clot causing their symptoms and that speed matters, which is why consent and administration happen quickly once eligibility is confirmed. Tell the patient and family that any needle sticks, injections or arterial punctures are avoided during and after the infusion specifically to reduce bleeding risk.
After the infusion, teach the patient to report any new symptom immediately rather than waiting: a headache that feels different from before, new bruising, blood in urine or stool, or bleeding from the gums. Reassure them that frequent neuro checks in the first hours are routine monitoring, not a sign that something has gone wrong, so they are not alarmed by the intensity of observation.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
How often are neuro checks done after alteplase for stroke?
Every 15 minutes for the first hour, then every 30 minutes for the next six hours, then hourly until 24 hours have passed, following the standard post-thrombolysis monitoring schedule. Exact intervals follow institutional protocol.
What is the treatment window for alteplase in ischaemic stroke?
Up to 4.5 hours from symptom onset in most protocols, though eligibility also depends on imaging findings, blood pressure, and exclusion criteria such as recent surgery or anticoagulant use.
Why can't you give injections after starting alteplase?
Any puncture site becomes a bleeding risk while the drug is actively dissolving fibrin, since the clot sealing that puncture can be broken down along with the pathological clot. IV access should be secured before the infusion starts for this reason.
What should a nurse do if a patient develops a severe headache during alteplase infusion?
Stop the infusion, notify the provider immediately, and treat it as a possible intracranial haemorrhage until imaging rules it out. This is a medical emergency, not a symptom to monitor and reassess later.
More on pharmacology
Guides on this